Genetic variation in the endocannabinoid system and response to cognitive behavioural therapy for child anxiety disorders

[thumbnail of Open access]
Preview
Text (Open access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.
| Preview
Available under license: Creative Commons Attribution
[thumbnail of Lester et al_Genetic variation in the endocannabinoid system and response to CBT for child anxiety disorders_2016.pdf]
Preview
Text - Accepted Version
· Please see our End User Agreement before downloading.
| Preview

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Lester, K. J., Coleman, J. R. I., Roberts, S., Keers, R., Breen, G., Bogels, S., Creswell, C., Hudson, J. L., McKinnon, A., Nauta, M., Rapee, R. M., Schneider, S., Silverman, W. K., Thastum, M., Waite, P. orcid id iconORCID: https://orcid.org/0000-0002-1967-8028, Wergeland, G. J. H. and Eley, T. C. (2017) Genetic variation in the endocannabinoid system and response to cognitive behavioural therapy for child anxiety disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 174 (2). pp. 144-155. ISSN 1552-485X doi: 10.1002/ajmg.b.32467

Abstract/Summary

Extinction learning is an important mechanism in the successful psychological treatment of anxiety. Individual differences in response and relapse following Cognitive Behavior Therapy may in part be explained by variability in the ease with which fears are extinguished or the vulnerability of these fears to re-emerge. Given the role of the endocannabinoid system in fear extinction, this study investigates whether genetic variation in the endocannabinoid system explains individual differences in response to CBT. Children (N = 1,309) with a primary anxiety disorder diagnosis were recruited. We investigated the relationship between variation in the CNR1, CNR2, and FAAH genes and change in primary anxiety disorder severity between pre- and post-treatment and during the follow-up period in the full sample and a subset with fear-based anxiety disorder diagnoses. Change in symptom severity during active treatment was nominally associated (P < 0.05) with two SNPs. During the follow-up period, five SNPs were nominally associated with a poorer treatment response (rs806365 [CNR1]; rs2501431 [CNR2]; rs2070956 [CNR2]; rs7769940 [CNR1]; rs2209172 [FAAH]) and one with a more favorable response (rs6928813 [CNR1]). Within the fear-based subset, the effect of rs806365 survived multiple testing corrections (P < 0.0016). We found very limited evidence for an association between variants in endocannabinoid system genes and treatment response once multiple testing corrections were applied. Larger, more homogenous cohorts are needed to allow the identification of variants of small but statistically significant effect and to estimate effect sizes for these variants with greater precision in order to determine their potential clinical utility.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/65725
Identification Number/DOI 10.1002/ajmg.b.32467
Refereed Yes
Divisions Life Sciences > School of Psychology and Clinical Language Sciences > Department of Psychology
Life Sciences > School of Psychology and Clinical Language Sciences > Development
Life Sciences > School of Psychology and Clinical Language Sciences > Psychopathology and Affective Neuroscience
Life Sciences > School of Psychology and Clinical Language Sciences > Anxiety and Depression in Young People (AnDY)
Publisher Wiley
Download/View statistics View download statistics for this item

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar